Zobrazeno 1 - 10
of 14
pro vyhledávání: '"J. W. M. Martens"'
Autor:
F. V. Reinema, F. C. G. J. Sweep, G. J. Adema, W. J. M. Peeters, J. W. M. Martens, J. Bussink, P. N. Span
Publikováno v:
Cancer & Metabolism, Vol 11, Iss 1, Pp 1-14 (2023)
Abstract Background Recently, we reported that tamoxifen-resistant (TAM-R) breast cancer cells are cross-resistant to irradiation. Here, we investigated the mechanisms associated with tamoxifen-induced radioresistance, aiming to prevent or reverse re
Externí odkaz:
https://doaj.org/article/65e65290676f4fa18d55dcd8e0866ed2
Autor:
Danielle E. Desa, Robert L. Strawderman, Wencheng Wu, Robert L. Hill, Marcel Smid, J. W. M. Martens, Bradley M. Turner, Edward B. Brown
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Metastases are the leading cause of breast cancer-related deaths. The tumor microenvironment impacts cancer progression and metastatic ability. Fibrillar collagen, a major extracellular matrix component, can be studied using the l
Externí odkaz:
https://doaj.org/article/fdbdba99c78b4fe0a6cbb731ab32a392
Autor:
R. R. J. Coebergh van den Braak, S. ten Hoorn, A. M. Sieuwerts, J. B. Tuynman, M. Smid, S. M. Wilting, J. W. M. Martens, C. J. A. Punt, J. A. Foekens, J. P. Medema, J. N. M. IJzermans, L. Vermeulen
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background There are profound individual differences in clinical outcomes between colorectal cancers (CRCs) presenting with identical stage of disease. Molecular stratification, in conjunction with the traditional TNM staging, is a promising
Externí odkaz:
https://doaj.org/article/d6c7c6e7e2db4724b5be3c4143803535
Autor:
I. E. de Kruijff, A. M. Sieuwerts, N. Beije, W. J. C. Prager - van der Smissen, L. Angus, C. M. Beaufort, M. N. Van, E. Oomen - de Hoop, A. Jager, P. Hamberg, F. E. de Jongh, J. Kraan, J. W. M. Martens, S. Sleijfer
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundCisplatin (cDDP) has regained interest for metastatic breast cancer (MBC) patients, given the platinum sensitivity in subtypes and better manageable toxicity. Here, the primary aim was to determine whether molecular characteristics of circu
Externí odkaz:
https://doaj.org/article/3ecfd168a49445039557708262e8b2a4
Autor:
M. K. Bos, S. W. Lam, G. Motta, J. C. A. Helmijr, C. M. Beaufort, E. de Jonge, J. W. M. Martens, E. Boven, M. P. H. M. Jansen, A. Jager, S. Sleijfer
Publikováno v:
Bos, M K, Lam, S W, Motta, G, Helmijr, J C A, Beaufort, C M, de Jonge, E, Martens, J W M, Boven, E, Jansen, M P H M, Jager, A & Sleijfer, S 2023, ' Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer ', Breast Cancer Research and Treatment, vol. 200, no. 2, pp. 271-279 . https://doi.org/10.1007/s10549-023-06965-5
Breast Cancer Research and Treatment, 200(2), 271-279. Springer New York
Breast Cancer Research and Treatment, 200(2), 271-279. Springer New York
Background ESR1 mutations have been identified as mechanism for endocrine resistance and are also associated with a decreased overall survival. We assessed ESR1 mutations in circulating tumor DNA (ctDNA) for impact on outcome to taxane-based chemothe
Autor:
R. R. J. Coebergh Van Den Braak, S. Ten Hoorn, A. M. Sieuwerts, J. B. Tuynman, M. Smid, S. M. Wilting, J. W. M. Martens, C. J. A. Punt, J. A. Foekens, J. P. Medema, J. N. M. IJzermans, Vermeulen, L.
Additional file 1: Supplementary Table S1. Distribution of CMS per tumor stage in the total and individual cohorts. Supplementary Figure S1. Distribution of the molecular subtypes per tumor stage in the individual cohorts. Supplementary Figure S2. Ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd1af1c3fc9f0bba7330f54d4cbe906
Autor:
C.C. van Donkelaar, J. W. M. Martens, J.M.J. den Toonder, S. SahebAli, M. Tuerlings, A. Hollestelle, Regina Luttge, H. Eslami Amirabadi
Publikováno v:
Biomedical Microdevices, 21(4):101. Kluwer Academic
Biomedical Microdevices
Biomedical Microdevices, 21(4):101. Kluwer Academic Publishers
Biomedical Microdevices, 4, 21
Biomedical Microdevices
Biomedical Microdevices, 21(4):101. Kluwer Academic Publishers
Biomedical Microdevices, 4, 21
E-cadherin is a cell-cell adhesion protein that plays a prominent role in cancer invasion. Inactivation of E-cadherin in breast cancer can arise from gene promoter hypermethylation or genetic mutation. Depending on their E-cadherin status, breast can
Autor:
S, Moghadasi, V, Grundeken, L A M, Janssen, N H, Dijkstra, M, Rodríguez-Girondo, W A G, van Zelst-Stams, J C, Oosterwijk, M G E M, Ausems, R A, Oldenburg, M A, Adank, E W, Blom, M W G, Ruijs, T A M, van Os, C H M, van Deurzen, J W M, Martens, C P, Schroder, J T, Wijnen, M P G, Vreeswijk, C J, van Asperen
Publikováno v:
Clinical genetics. 93(1)
To establish whether existing mutation prediction models can identify which male breast cancer (MBC) patients should be offered BRCA1 and BRCA2 diagnostic DNA screening, we compared the performance of BOADICEA (Breast and Ovarian Analysis of Disease
Publikováno v:
Journal of the National Cancer Institute. 106(9)
Autor:
P N, Span, G, Pollakis, W A, Paxton, F C G J, Sweep, J A, Foekens, J W M, Martens, A M, Sieuwerts, H W M, van Laarhoven
Publikováno v:
International journal of cancer. 136(1)
The CC-chemokine receptor CCR5 has been associated with cancer progression and metastasis. CCR5 blockers such as Maraviroc are tested in metastatic cancer patients. A mutant allele of CCR5, CCR5-delta32 (CCR5del32), which encodes for a protein with a